Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level

Cell Death and Differentiation

Volumn 18, Issue 4, 2011, Pages 700-711

  Morizot, A ^a,b   Merino D ^a,b   Lalaoui, N ^a,b   Jacquemin, G ^a,b   Granci, V ^a,b   Iessi, E ^a,b   Lanneau, D ^a,b   Bouyer, F ^a,b   Solary, E ^a,b,c,d   Chauffert, B ^a,b,e   Saas, P ^f,g,h   Garrido, C ^a,b   Micheau, O ^a,b,e  

^a Chu   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c Universite Paris Sud   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e CENTRE GEORGES FRANÇOIS LECLERC   (France)

^f INSERM   (France)

^g ETABLISSEMENT FRANÇAIS DU SANG   (France)

^h UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

apoptosis; c FLIP; chemotherapy; TRAIL; TRAIL R4

Indexed keywords

CASPASE 8; CISPLATIN; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR 4; ETOPOSIDE; FLICE INHIBITORY PROTEIN; FLUOROURACIL; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CELL LINE, TUMOR; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; DRUG RESISTANCE, NEOPLASM; GPI-LINKED PROTEINS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA INTERFERENCE; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

MUS MUSCULUS;

EID: 79952630372     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2010.144     Document Type: Article

References (38)

1. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008; 26: 3621-3630.
2. Merino D, Lalaoui N, Morizot A, Solary E, Micheau O. TRAIL in cancer therapy: present and future challenges. Expert opin ther targets 2007; 11: 1299-1314. (Pubitemid 47604070)
3. Berg D, Lehne M, Muller N, Siegmund D, Munkel S, Sebald W et al. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ 2007; 14: 2021-2034.
4. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 2004; 11(Suppl 1): S86-S96. (Pubitemid 39136801)
5. Lacour S, Micheau O, Hammann A, Drouineaud V, Tschopp J, Solary E et al. Chemotherapy enhances TNF-related apoptosis-inducing Ligand DISC assembly in HT29 human colon cancer cells. Oncogene 2003; 22: 1807-1816. (Pubitemid 36519144)
6. Ndozangue-Touriguine O, Sebbagh M, Merino D, Micheau O, Bertoglio J, Breard J. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 2008; 27: 6012-6022.
7. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8: 274-281. (Pubitemid 34250106)
8. Sanlioglu AD, Karacay B, Koksal IT, Griffith TS, Sanlioglu S. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Cancer Gene Ther 2007; 14: 976-984. (Pubitemid 350115354)
9. Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B et al. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys 2007; 69: 716-723. (Pubitemid 47418395)
10. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 2005; 90: 612-624. (Pubitemid 40780880)
11. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833-2840. (Pubitemid 28425704)
12. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006; 26: 7046-7055. (Pubitemid 44477684)
13. Llobet D, Eritja N, Encinas M, Llecha N, Yeramian A, Pallares J et al. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene 2008; 27: 2513-2524. (Pubitemid 351550887)
14. Travert M, Ame-Thomas P, Pangault C, Morizot A, Micheau O, Semana G et al. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol 2008; 181: 1001-1011.
15. von Haefen C, Gillissen B, Hemmati PG, Wendt J, Guner D, Mrozek A et al. Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 2004; 23: 8320-8332. (Pubitemid 39531843)
16. Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K, Johnston PG. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 2005; 4: 2026-2036. (Pubitemid 43056986)
17. Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP et al. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Cancer res 2010; 70: 1101-1110.
18. Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 2010; 28: 1527-1533.
19. Koornstra JJ, Kleibeuker JH, van Geelen CM, Rijcken FE, Hollema H, de Vries EG et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 2003; 200: 327-335. (Pubitemid 36827307)
20. Ganten TM, Sykora J, Koschny R, Batke E, Aulmann S, Mansmann U et al. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med 2009; 87: 995-1007.
21. Granci V, Bibeau F, Kramar A, Boissiere-Michot F, Thezenas S, Thirion A et al. Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas. Eur J Cancer 2008; 44: 2312-2318.
22. Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 2009; 459: 428-432.
23. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer res 2000; 60: 847-853. (Pubitemid 30129513)
24. Nguyen DM, Yeow WS, Ziauddin MF, Baras A, Tsai W, Reddy RM et al. The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death. Cancer J 2006; 12: 257-273. (Pubitemid 44285552)
25. Ruiz-Ruiz C, Lopez-Rivas A. Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells. Biochem J 2002; 365 (Part 3): 825-832. (Pubitemid 34864466)
26. Wilson TR, McLaughlin KM, McEwan M, Sakai H, Rogers KM, Redmond KM et al. c-FLIP: a key regulator of colorectal cancer cell death. Cancer res 2007; 67: 5754-5762. (Pubitemid 46985008)
27. Mirandola P, Ponti C, Gobbi G, Sponzilli I, Vaccarezza M, Cocco L et al. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood 2004; 104: 2418-2424. (Pubitemid 39331842)
28. Dumitru CA, Carpinteiro A, Trarbach T, Hengge UR, Gulbins E. Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. Apoptosis 2007; 12: 1533-1541. (Pubitemid 46988288)
29. Xu L, Qu X, Zhang Y, Hu X, Yang X, Hou K et al. Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts. FEBS Lett 2009; 583: 943-948.
30. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006; 25: 838-848. (Pubitemid 43237702)
31. Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. JBiol Chem 1999; 274: 7987-7992.
32. Rebillard A, Jouan-Lanhouet S, Jouan E, Legembre P, Pizon M, Sergent O et al. Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells. Eur J Cancer 2010; 46: 1445-1455.
33. Kohler B, Anguissola S, Concannon CG, Rehm M, Kogel D, Prehn JH. Bid participates in genotoxic drug-induced apoptosis of HeLa cells and is essential for death receptor ligands' apoptotic and synergistic effects. PLoS One 2008; 3: e2844.
34. Ullenhag GJ, Mukherjee A, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 2007; 13: 5070-5075. (Pubitemid 47502072)
35. Koksal IT, Sanlioglu AD, Karacay B, Griffith TS, Sanlioglu S. Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urol Oncol 2008; 26: 158-165. (Pubitemid 351288560)
36. Schneider P. Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins. Methods Enzymol 2000; 322: 325-345. (Pubitemid 30482067)
37. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3587-3596.
38. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol cell 2001; 8: 705-711.